WO2016031264A1 - Agent d'augmentation du volume des muscles squelettiques et son utilisation - Google Patents
Agent d'augmentation du volume des muscles squelettiques et son utilisation Download PDFInfo
- Publication number
- WO2016031264A1 WO2016031264A1 PCT/JP2015/053580 JP2015053580W WO2016031264A1 WO 2016031264 A1 WO2016031264 A1 WO 2016031264A1 JP 2015053580 W JP2015053580 W JP 2015053580W WO 2016031264 A1 WO2016031264 A1 WO 2016031264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meclizine
- congenital
- syndrome
- muscle
- skeletal muscle
- Prior art date
Links
- 210000002027 skeletal muscle Anatomy 0.000 title claims abstract description 36
- 239000004067 bulking agent Substances 0.000 title claims abstract description 20
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims abstract description 94
- 229960001474 meclozine Drugs 0.000 claims abstract description 88
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 25
- 210000003205 muscle Anatomy 0.000 claims description 24
- 208000001076 sarcopenia Diseases 0.000 claims description 18
- 201000006938 muscular dystrophy Diseases 0.000 claims description 17
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- 208000011580 syndromic disease Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 206010028289 Muscle atrophy Diseases 0.000 claims description 10
- 201000000585 muscular atrophy Diseases 0.000 claims description 9
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims description 8
- 206010010356 Congenital anomaly Diseases 0.000 claims description 8
- 201000002481 Myositis Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 206010066871 Disuse syndrome Diseases 0.000 claims description 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 7
- 208000029549 Muscle injury Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 7
- 206010058907 Spinal deformity Diseases 0.000 claims description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 201000001981 dermatomyositis Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000016245 inborn errors of metabolism Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 230000003137 locomotive effect Effects 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 206010039722 scoliosis Diseases 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 206010023509 Kyphosis Diseases 0.000 claims description 6
- 208000010316 Myotonia congenita Diseases 0.000 claims description 6
- 201000011474 congenital myopathy Diseases 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 208000005987 polymyositis Diseases 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000020763 muscle atrophy Effects 0.000 claims description 5
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 5
- 238000012549 training Methods 0.000 claims description 5
- 238000009360 aquaculture Methods 0.000 claims description 4
- 244000144974 aquaculture Species 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 230000001272 neurogenic effect Effects 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 3
- 229940018415 meclizine hydrochloride Drugs 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 206010053159 Organ failure Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 38
- 230000004069 differentiation Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 15
- 230000006698 induction Effects 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 238000010599 BrdU assay Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
- 238000000719 MTS assay Methods 0.000 description 5
- 231100000070 MTS assay Toxicity 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003098 myoblast Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940124602 FDA-approved drug Drugs 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100032975 Myosin-1 Human genes 0.000 description 3
- 101710204036 Myosin-1 Proteins 0.000 description 3
- 102100038934 Myosin-7 Human genes 0.000 description 3
- 101710204029 Myosin-7 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000012758 nuclear staining Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000015580 Increased body weight Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000004364 Myogenin Human genes 0.000 description 2
- 108010056785 Myogenin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- -1 inorganic acid salts Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000003131 sacroiliac joint Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100030913 Acetylcholine receptor subunit alpha Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 102100024108 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 101000726895 Homo sapiens Acetylcholine receptor subunit alpha Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100351033 Mus musculus Pax7 gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009511 drug repositioning Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000015585 poly-pyrimidine tract binding protein Human genes 0.000 description 1
- 108010063723 poly-pyrimidine tract binding protein Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Definitions
- the present invention relates to a skeletal muscle bulking agent and use thereof.
- the skeletal muscle bulking agent of the present invention is used, for example, for the treatment of sarcopenia.
- Muscle loss such as sarcopenia
- Muscle loss that causes a decrease in skeletal muscle mass is considered to be one of the causes of reduced mobility, falling fractures, and vulnerability in the elderly.
- the treatment is seen as a trump card for maintaining a healthy life expectancy.
- There is no fundamental cure for sarcopenia and exercise therapy, nutrition therapy, and pharmacotherapy have been attempted, but there are still no effective treatments due to adherence and side effects.
- the causes of sarcopenia include various factors such as changes in age-related hormone balance, age-related changes in muscles and nerves, changes in disuse due to other diseases and social factors, and inadequate intake of amino acids and vitamins due to undernutrition. Predisposing factors are considered to be involved in multiple ways. Therefore, the fundamental treatment is difficult, and the development of a new treatment method is required.
- skeletal muscle loss is the main cause or cause of various diseases in addition to sarcopenia and other muscle loss. Many of these diseases have not yet been established as appropriate treatments, and there is a need to provide new treatments.
- a main problem of the present invention is to provide a novel treatment strategy for a disease whose main cause or part of the etiology is skeletal muscle loss.
- the present inventors tried to find a low molecular weight compound effective for increasing the amount of skeletal muscle from among already approved drugs.
- FDA-approved drug library Prestwick ⁇ Chemicals
- 320 types that can be clinically applied in Japan and that can be administered for a long period of time are selected, and a sub-library is created to screen for effective compounds. did.
- meclizine has a cell proliferation promoting effect and a differentiation inhibiting effect. It was. That is, meclizine was selected as a very promising compound.
- the therapeutic agent according to [3], wherein the disease is sarcopenia.
- the above-mentioned diseases include muscle damage due to trauma or surgery, disuse muscular atrophy, disuse syndrome, easy fall, neurogenic muscular atrophy, osteoporosis, osteoarthritis, osteoarthritis, scoliosis and posterior Spinal deformity such as mania, obesity, rheumatoid arthritis, dermatomyositis, polymyositis, myositis associated with autoimmune diseases, locomotive syndrome, metabolic syndrome, motor organ instability, dynapenia, flail, rhabdomyolysis, It is a disease selected from the group consisting of cachexia due to muscular dystrophy, congenital myopathy, congenital myasthenia syndrome, congenital hypoplasia, congenital metabolic disorders, impaired glucose tolerance or diabetes or cancer, [3 ] The therapeutic agent as described in.
- a method for treating bone system diseases comprising a step of administering to a patient with cachexia due to cancer or
- a method for treating muscular dystrophy comprising the step of administering meclizine or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a patient with muscular dystrophy.
- a physical training or physical exercise supplement containing a meclizine or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention relates to a skeletal muscle bulking agent and use thereof.
- the present invention is based on a result of finding a novel effect of meclizine, that is, an effect of increasing skeletal muscle mass.
- meclizine promotes myoblast proliferation while reversibly inhibiting its differentiation is worthy of special mention.
- the skeletal muscle bulking agent of the present invention contains meclizine or a pharmaceutically acceptable salt thereof as an active ingredient.
- Meclizine is a compound of the substance name 1-[(4-chlorophenyl) phenylmethyl] -4-[(3-methylphenyl) methyl] piperazine and is known as a kind of antihistamine.
- Meclizine is sold as an over-the-counter (OTC) as a motion sickness medicine.
- OTC over-the-counter
- Meclizine is sometimes referred to as meclozine.
- meclizine and the term “meclozin” are used interchangeably.
- a pharmacologically acceptable salt of meclizine may be used as the active ingredient of the skeletal muscle bulking agent of the present invention.
- Commercial meclizine preparations are often formulated in the form of meclizine hydrochloride. Therefore, the hydrochloride is also preferably used in the present invention.
- the “pharmacologically acceptable salt” is not limited to this, and various salts such as an acid addition salt and an amino acid addition salt are assumed.
- acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, hydrobromide, acetate, maleate, fumarate, citrate, benzenesulfonate, Organic acid salts such as benzoate, malate, oxalate, methanesulfonate, and tartrate are listed.
- amino acid addition salts include glycine addition salts, phenylalanine addition salts, lysine addition salts, aspartic acid addition salts, and glutamic acid addition salts.
- Muscles are roughly classified into skeletal muscles, smooth muscles and myocardium. Skeletal muscle is composed of muscle cells (muscle fibers) and connective tissue. Skeletal muscles are also called voluntary muscles and are histologically striated muscles. In addition to the role of moving the body, skeletal muscle has various roles such as maintaining posture, stabilizing joints, generating heat, and protecting blood vessels and organs.
- the skeletal muscle bulking agent of the present invention can be applied to the treatment or prevention of diseases whose main cause or part of the pathogenesis is skeletal muscle loss. That is, the present invention also provides a therapeutic agent for the disease (containing a skeletal muscle bulking agent).
- “Therapeutic agent” refers to a drug that exhibits a therapeutic or prophylactic effect on a target disease or condition.
- Therapeutic effects include alleviation of symptoms or concomitant symptoms characteristic of the target disease / pathology (lightening), prevention or delay of worsening of symptoms, and the like.
- the latter can be regarded as one of the preventive effects in terms of preventing the seriousness.
- the therapeutic effect and the preventive effect are partially overlapping concepts, and it is difficult to clearly distinguish them from each other, and there is little benefit in doing so.
- a typical preventive effect is to prevent or delay the recurrence of symptoms characteristic of the target disease / pathology.
- it shows some therapeutic effect or preventive effect with respect to a target disease / pathology, or both, it corresponds to the therapeutic agent with respect to a target disease / pathology.
- a disease in which a decrease in skeletal muscle is the main cause or a part of the etiology is, for example, sarcopenia typified by sarcopenia.
- Other spinal deformities such as muscle damage due to trauma and surgery, disuse muscle atrophy, disuse syndrome, easy fall, neurogenic muscle atrophy, osteoporosis, osteoarthritis, osteoarthritis, scoliosis and kyphosis , Obesity, rheumatoid arthritis, dermatomyositis, polymyositis, myositis associated with autoimmune disease, locomotive syndrome, metabolic syndrome, motor organ instability, dynapenia, flail, rhabdomyolysis, muscular dystrophy, congenital
- the therapeutic agent of the present invention can also be applied to myopathy, congenital myasthenia syndrome, congenital hypoplasia, congenital metabolic disorders, impaired glucose tolerance or cachexia due to diabetes or cancer.
- the preparation of the therapeutic agent of the present invention can be performed according to a conventional method.
- other pharmaceutically acceptable ingredients for example, carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, preservatives, physiological Saline solution and the like.
- excipient lactose, starch, sorbitol, D-mannitol, sucrose and the like can be used.
- disintegrant starch, carboxymethylcellulose, calcium carbonate and the like can be used. Phosphate, citrate, acetate, etc. can be used as the buffer.
- emulsifier gum arabic, sodium alginate, tragacanth and the like can be used.
- suspending agent glyceryl monostearate, aluminum monostearate, methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, sodium lauryl sulfate and the like can be used.
- soothing agent benzyl alcohol, chlorobutanol, sorbitol and the like can be used.
- stabilizer propylene glycol, ascorbic acid or the like can be used.
- preservatives phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben, and the like can be used.
- preservatives benzalkonium chloride, paraoxybenzoic acid, chlorobutanol and the like can be used.
- the dosage form for formulation is not particularly limited. Examples of dosage forms are tablets, powders, fine granules, granules, capsules, syrups, injections, external preparations, and suppositories.
- the therapeutic agent of the present invention is administered orally or parenterally (intravenous, intraarterial, subcutaneous, intradermal, intramuscular, or intraperitoneal injection, transdermal, nasal, transmucosal, etc.) depending on the dosage form.
- Applies to Systemic and local administration are also indicated by the subject. These administration routes are not mutually exclusive, and two or more arbitrarily selected can be used in combination (for example, intravenous injection or the like is performed simultaneously with oral administration or after a predetermined time has elapsed).
- the therapeutic agent of the present invention contains an active ingredient in an amount necessary for obtaining an expected therapeutic effect (that is, a therapeutically effective amount).
- the amount of the active ingredient in the therapeutic agent of the present invention generally varies depending on the dosage form, but the amount of the active ingredient is set, for example, within the range of about 0.1 wt% to about 99 wt% so as to achieve a desired dose.
- the dosage of the therapeutic agent of the present invention is set so as to obtain the expected therapeutic effect.
- symptoms symptoms, patient age, sex, weight, etc. are generally considered.
- a person skilled in the art can set an appropriate dose in consideration of these matters.
- the dose can be set so that the amount of active ingredient per day is 1 mg to 500 mg, preferably 5 mg to 300 mg, particularly preferably 10 mg to 200 mg.
- the administration schedule for example, once to several times a day, once every two days, or once every three days can be adopted. In preparing the administration schedule, the patient's medical condition and the duration of effect of the active ingredient can be taken into consideration.
- treatment with another medicine for example, existing therapeutic agent
- the existing therapeutic technique may be combined with the treatment with the therapeutic agent of the present invention.
- the present application is intended for diseases mainly caused by skeletal muscle loss (muscle loss such as sarcopenia, muscle damage due to trauma or surgery, disuse muscle atrophy, disuse syndrome, Falls, neurogenic muscle atrophy, osteoporosis, osteoarthritis, osteoarthritis, spinal deformity such as scoliosis and kyphosis, obesity, rheumatoid arthritis, dermatomyositis, polymyositis, myositis associated with autoimmune diseases, Locomotive syndrome, metabolic syndrome, motor organ instability, dynapenia, flail, rhabdomyolysis, muscular dystrophy, congenital myopathy, congenital myasthenia syndrome, congenital hypoplasia, congenital metabolic disorders, There is also provided a therapeutic method characterized by administering a therapeutically effective amount of the therapeutic agent of the present invention to a patient with impaired glucose tolerance or cachexia due to diabetes or cancer.
- skeletal muscle loss muscle loss
- disuse muscle atrophy disuse muscle
- the skeletal muscle bulking agent of the present invention can also be used as a supplementary nutrient for physical training / physical exercise for the purpose of increasing or strengthening muscles.
- the “supplementary nutrient” used herein is used to promote the effects of physical training / physical exercise, and has a higher effect than when it is not used.
- a supplementary nutritional supplement it can also be provided in the form of a food composition containing it in addition to the form (dosage form) similar to the therapeutic agent.
- a food composition for example, it is provided in the form of powder, granule powder, tablet, paste, liquid or the like as a dietary supplement (supplement, nutrition drink, etc.).
- the food composition of the present invention preferably contains an active ingredient in such an amount that a desired effect, that is, an increase in muscle can be expected.
- the addition amount can be determined in consideration of the age, physique (height, weight, etc.), gender, etc. of the subject (user) in which it is used.
- the skeletal muscle bulking agent of the present invention is also useful in the fields of animal husbandry, pets (animals) and aquaculture.
- livestock cattle, pig, horse, sheep, etc.
- poultry chicken, duck, goose, turkey, quail
- Pheasants, etc. fish
- fish una, red sea bream, yellowtail, etc.
- the present invention can also be used as a meat volume increasing agent. It is also possible to use the skeletal muscle bulking agent of the present invention for maintaining the health and body shape of pets.
- Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome. Hum. Mol. Genet., 18, 1229-1237.).
- Hu5 / KD3 cell line (distributed by National Longevity Medical Research Center, Director Yasuhiro Hashimoto) is a cell line in which telomerase is continuously expressed in human myoblasts. Differentiate into myotubes with induction medium (Shiomi K et al. Gene Ther. 2011; 18: 857-866). Two types of media are used for culturing the Hu5 / KD3 cell line.
- pmGM (20% fetal bovine serum (FBS, Thermo Scientific), 2% Ultroser G (Biosepra, PALL), penicillin G (100 u / ml) and streptomycin sulfate (100 ⁇ g / ml)
- Penstrep Dulbecco's Modified Eagle's Medium
- pmDM 2% horse serum, 1% insulin-transferrin-selenate (ITS, Invitrogen)
- penicillin G 100 u / ml
- streptomycin sulfate 100 ⁇ g / ml
- the cultured cells were buffered (50 mM HEPES pH 7.0, 150 mM NaCl, 10% glycerol, 1% TritonX-100, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 1 ⁇ g / ⁇ l aprotinin, 1 ⁇ g / ⁇ l leupeptin, 1 ⁇ g / ⁇ l pepstatin A, 1 mM PMSF, 1 mM sodium orthovanadate). All proteins were dissolved in 1 ⁇ laemmli buffer, separated by SDS-PAGE (10% or 7.5% gel), and transferred to a PVDF membrane (Immobilon-P, Millipore).
- All proteins were dissolved in 1 ⁇ laemmli buffer, separated by SDS-PAGE (10% or 7.5% gel), and transferred to a PVDF membrane (Immobilon-P, Millipore).
- the transferred membrane was washed with a Tris buffer containing 0.05% Tween 20 (TBS-T) and then blocked with TBS-T containing 3% bovine serum albumin (room temperature, 1 hour). Subsequently, the treated membrane was reacted with mouse anti-MYH monoclonal antibody (H-300, Santa Cruz Biotechnology, dilution 1: 200) or anti-GAPDH antibody (G9545, Sigma-Aldrich, dilution 1: 600) (4 ° C overnight. The membrane was washed three times and then reacted with a secondary antibody (HRP-labeled goat anti-rabbit IgG antibody (GE Healthcare, 1: 6000)) (room temperature, 1 hour). Detection was performed using Amersham ECL Western blotting detection reagents (GE Healthcare), and quantification was performed using the ImageJ program.
- TBS-T Tris buffer containing 0.05% Tween 20
- TBS-T Tris buffer containing 0.05% bovine serum albumin
- the BrdU assay is a method for quantifying cell division and is used to evaluate cell proliferation in the same manner as the MTS assay. Also in the BrdU assay, meclizine showed a cell growth promoting action (FIG. 3).
- the morphology of cells on differentiation induction day 7 was compared with and without meclizine (control) (FIG. 4).
- control meclizine
- formation of myotube myotube
- myotubes are not observed in cells administered with meclizine.
- Differentiation is suppressed by meclizine, which is a morphologically undifferentiated state.
- MYH myosin heavy chain protein
- Myosin heavy chain protein is a structural protein of muscle expressed at the end of differentiation.
- DAPI nuclear staining was used as a control for cell number.
- meclizine suppressed the expression of myosin heavy chain protein (FIG. 5).
- Western blot analysis also showed that meclizine suppressed the expression of myosin heavy chain protein (MYH) in cells on day 7 of differentiation induction (FIG. 6).
- the gene expression level of myosin heavy chain protein (MYH) was compared by quantitative RT-PCR. Evaluation by quantitative RT-PCR was performed as follows. First, total RNA was isolated from cells using Trizol (Life Technologies). First strand cDNA was synthesized with ReverTra Ace (Toyobo). Using LightCycler 480 Real-Time PCR (Roche) and SYBR Green (Takara), mRNA expression levels of myosin heavy chain 1 (MYH1), myosin heavy chain 7 (MYH7), myogenin (MYOG), Pax7 and dystrophin (DMD) It was measured. The mRNA level was corrected by the expression level of GAPDH.
- MYH1 myosin heavy chain 1
- MYH7 myosin heavy chain 7
- MYOG myogenin
- DMD dystrophin
- Method C57BL / 6J mice were fed a special feed (meclizine-containing feed (4 g / 10 kg) or control feed) from the 16th day of birth (0w) and reared in a cage. On the 23rd day after birth (1w), the 30th day after birth (2w) and the 37th day after birth (3w), body weight was measured. The animals were sacrificed on the 37th day after birth, and X-ray photography and micro CT measurement were performed. Micro CT measurement was performed according to the following procedure. First, the whole body of the mouse was scanned with a 35 ⁇ m wide slice in a cross section perpendicular to the body axis.
- the mouse sacroiliac joint was Merckmar, and the vertebral body with the sacroiliac joint was the first sacrum.
- the fourth lumbar vertebral body was identified starting from the first sacrum.
- the body axis cross-sectional image data at the fourth and fifth lumbar intervertebral intervertebral discs were taken into the image analysis software.
- the muscle cross-sectional area of the paraspinal muscles (vertical spine and multifidus) was measured with image analysis software (FIG. 16). Three slice images were measured per intervertebral space.
- MDX mice muscle dystrophy model mice
- a special feed meclizine-containing feed (4g / 10kg) or control feed
- 21st day (0w) to the 49th day (4w) after birth. Reared in The body weight was measured on the 28th day after birth (1w), the 35th day after birth (2w), the 42nd day after birth (3w), and the 49th day after birth (4w).
- the meclizine-administered mouse had a larger paraspinal muscle cross-sectional area than the control (FIG. 17).
- the results are shown as a ratio to the control.
- meclizine was found to increase body weight and paraspinal muscle cross-sectional area in normal mice.
- ⁇ Summary> Meclizine inhibited human myoblast differentiation and promoted proliferation in a dose-dependent manner. ⁇ The differentiation inhibitory effect of meclizine was reversible. • Mice receiving meclizine increased body weight and muscle cross-sectional area. ⁇ Meclizine also increased body weight in muscular dystrophy model mice. For muscular dystrophy, meclodin administration is expected to increase muscle mass and weight.
- the skeletal muscle bulking agent of the present invention contains meclizine, which is an already approved drug, as an active ingredient. Meclizine has an antihistamine effect and is marketed as an OTC (over-the-counter). It has been used safely for more than 50 years and has established safety such as optimal dose, side effects and contraindications. This fact is a great merit for clinical application.
- the therapeutic strategy using the skeletal muscle bulking agent of the present invention is not limited to sarcopenia and other disease groups (muscle damage caused by trauma or surgery, disuse).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention se rapporte au problème visant à fournir une nouvelle stratégie thérapeutique pour une affection de laquelle la perte de muscle squelettique est la cause principale ou partielle. L'invention concerne un agent d'augmentation du volume des muscles squelettiques contenant de la méclizine ou un sel pharmaceutiquement acceptable de celle-ci en tant que substance active.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-176248 | 2014-08-29 | ||
JP2014176248 | 2014-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016031264A1 true WO2016031264A1 (fr) | 2016-03-03 |
Family
ID=55399172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/053580 WO2016031264A1 (fr) | 2014-08-29 | 2015-02-10 | Agent d'augmentation du volume des muscles squelettiques et son utilisation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016031264A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024029173A1 (fr) * | 2022-08-03 | 2024-02-08 | 国立大学法人東海国立大学機構 | Agent pour la prévention ou l'amélioration de l'ostéoporose |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013032761A1 (fr) * | 2011-09-01 | 2013-03-07 | Kraft Foods Global Brands Llc | Gomme à mâcher pouvant être dégradée et procédé pour sa fabrication |
-
2015
- 2015-02-10 WO PCT/JP2015/053580 patent/WO2016031264A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013032761A1 (fr) * | 2011-09-01 | 2013-03-07 | Kraft Foods Global Brands Llc | Gomme à mâcher pouvant être dégradée et procédé pour sa fabrication |
Non-Patent Citations (6)
Title |
---|
MATSUSHITA M ET AL., PLOS ONE, vol. 8, no. 12, 2013, pages e81569 * |
MUCHIR A ET AL., SKELETAL MUSCLE, vol. 3, no. 17, 2013 * |
PRADO CMM ET AL., BRITISH JOURNAL OF CANCER, vol. 106, 2012, pages 1583 - 1586 * |
ROBERTS PJ ET AL., ONCOGENE, vol. 26, 2007, pages 3291 - 3310 * |
STROBEL S ET AL., ARTHRITIS RESEARCH & THERAPY, vol. 12, no. 2, 2010, pages R34 * |
TANNAPFEL A ET AL., GUT, vol. 52, 2003, pages 706 - 712 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024029173A1 (fr) * | 2022-08-03 | 2024-02-08 | 国立大学法人東海国立大学機構 | Agent pour la prévention ou l'amélioration de l'ostéoporose |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1759834B (zh) | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 | |
TWI314053B (en) | Use of compounds that are effective as selective opiate receptor modulators | |
KR101802411B1 (ko) | Fam19a5 단백질을 포함하는 비만 예방 또는 치료용 조성물 및 이를 이용한 비만 치료제의 스크리닝 방법 | |
JPH07507569A (ja) | ヒトの窒素保持の促進方法 | |
CN114126599A (zh) | 改变衰老相关分泌表型的方法和组合物 | |
JPWO2002074318A1 (ja) | Il−12発現調節剤 | |
WO2002060431A1 (fr) | Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires | |
WO2020175817A1 (fr) | Composition pour prévenir, atténuer ou traiter la fibrose | |
WO2016031264A1 (fr) | Agent d'augmentation du volume des muscles squelettiques et son utilisation | |
CN1777417B (zh) | PPARα激动剂和二甲双胍降低血清甘油三酯的用途 | |
CN111217885B (zh) | 木通皂苷d-有机酸的药物共晶体及其用途 | |
JP6716330B2 (ja) | ウロプラキン発現促進剤 | |
US12257260B2 (en) | Pharmaceutical use of anemoside B4 against acute gouty arthritis | |
JPH03135918A (ja) | 免疫賦活剤 | |
CN104114165B (zh) | 用于治疗憩室病的方法和组合物 | |
JP3738268B2 (ja) | インターロイキン−6産生抑制剤 | |
US20180030102A1 (en) | Application of metrnl protein in preparing hypolipidemic, hypoglycemic medicine | |
CN109771424B (zh) | 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用 | |
JP6566520B2 (ja) | 筋疾患の治療または予防のための医薬組成物 | |
CN116019801B (zh) | 用于促进内源性生长激素分泌的氨基酸组合物 | |
CN112915075A (zh) | 天门冬氨酸在预防或治疗肥胖症中的应用 | |
JP6977979B2 (ja) | 神経損傷治療又は予防用医薬 | |
CN117503789A (zh) | CMP-Neu5Ac在制备促进骨生长的食品及药物中的应用 | |
US20240424051A1 (en) | Composition for treating sarcopenia or osteoporosis through mechanism promoting formation of muscle fibers or inhibiting osteoclastogenesis, comprising cyclo-l-phenylalanyl-l-proline dipeptides | |
EP4544921A1 (fr) | Composition comprenant lactobacillus gasseri pour prévenir et traiter la sarcopénie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15835933 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15835933 Country of ref document: EP Kind code of ref document: A1 |